The market for viral therapies is expected to see a double digit compound annual growth for the next five years. To meet the market demand, viral vector manufacturing capacity growth is projected to be 18.5%. In this presentation, we will discuss building capacity to support live virus and viral vector production versus working with manufacturing partners with state-of-the-art facilities. We will discuss specific facility design considerations and modular approaches to delivering on the capacity need. The focus of the presentation will be a case study that highlights a state-of-the-art virotherapy manufacturing facility completed in just 13 months, due in part to the use of modular pre-fabricated clean rooms.